GlassScriptPhysician profile
Gregory J Quinlan
NPI 1588628333
$6,622.71
in general payments reported to CMS, 2019-2025
29 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.52 · 2022: $859 · 2023: $1,698 · 2024: $2,072 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,704.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,164.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,162.63 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.88 | 2022-2025 | Jardiance |
| Amgen INC. | $417.14 | 2022-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $375.03 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $367.50 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $355.54 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $333.52 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $295.42 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $277.37 | 2023-2025 | Onpattro, Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $241.58 | 2024 | Arcalyst |
| Novo Nordisk INC | $232.76 | 2022-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $189.75 | 2022-2025 | |
| Esperion Therapeutics, INC. | $181.20 | 2022-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $160.75 | 2022-2025 | Farxiga, Brilinta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $86.25 | 2022-2023 | Arcalyst |
| Daiichi Sankyo INC. | $53.59 | 2023-2024 | Injectafer |
| Abiomed | $47.30 | 2023-2024 | Impella |
| Lantheus Medical Imaging, INC. | $40.19 | 2023-2024 | Definity |
| Irhythm Technologies, INC. | $34.80 | 2023 | Zio Xt Patch |
| Edwards Lifesciences Corporation | $30.00 | 2025 | Sapien 3 Ultra Resilia |
| Biotronik INC. | $28.59 | 2025 | Pk Papyrus |
| Philips North America LLC | $24.19 | 2023 | |
| Bridgebio Pharma, INC. | $22.39 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $21.42 | 2022 | |
| Mannkind Corporation | $19.52 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.27 | 2023 | Inpefa |
| Vivaquant INC, Dba Rhythm Express | $15.89 | 2025 | Rhythm Express |
| Abbott Laboratories | $8.20 | 2023 | Assurity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Quinlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.